Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.
Qi Huang, Wen-Qi Cai, Zi-Wen Han, Moyu Wang, Yang Zhou, Jun-Ting Cheng, Ying Zhang, Yingying Wang, Qiang Xin, Xianwang Wang, Xiaochun Peng, Ying Xiang, Shuxian Fang, Zhaowu Ma, Hong-Yi Xin, Shuzhong Cui, Hong-Wu Xin
Abstract
designed the first OV-BiTE in 2014, which remarkably eradicated tumors in mice. Here we review the latest development of the structure, function, preclinical studies and/or clinical trials of BiTE and OV-BiTE and provide perspective views for optimizing the design of OV-BiTE. There is no doubt that OV-BiTE is becoming an exciting new platform for tumor immunotherapy and will enter clinical trial soon. Exploring the therapeutic effects and safety of OV-BiTE for synergistic tumor immunotherapy will bring new hope to tumor patients.